Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-09 |
2024-03 |
-0.3 |
-0.34 |
-0.04 |
-13.33% |
2024-03-05 |
2023-12 |
-0.36 |
-0.26 |
0.1 |
27.78% |
2024-03-05 |
2023-12 |
-0.36 |
N/A |
N/A |
N/A |
2023-11-08 |
2023-09 |
-0.35 |
-0.33 |
0.02 |
5.71% |
2023-11-08 |
2023-09 |
-0.35 |
N/A |
N/A |
N/A |
2023-08-09 |
2023-06 |
-0.34 |
-0.31 |
0.03 |
8.82% |
Date |
Firm |
Action |
From |
To |
2023-09-27 |
Piper Sandler |
Upgrade |
Overweight |
Overweight |
2023-08-09 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-14 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-03-27 |
B. Riley Securities |
Upgrade |
|
Buy |
2023-03-13 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-02-14 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-01-31 |
ALLEN ANDREW R |
Chief Executive Officer |
2.35M |
Stock Award(Grant) |
2024-01-31 |
CHO JAMES |
Officer |
138.64K |
Stock Award(Grant) |
2024-01-31 |
ECONOMIDES VASSILIKI NICHOLE |
Chief Financial Officer |
227.76K |
Stock Award(Grant) |
2024-01-31 |
HAWRYLUK MATTHEW PH.D. |
Officer |
286.88K |
Stock Award(Grant) |
2024-01-31 |
JONES ERIN |
Chief Operating Officer |
324.62K |
Stock Award(Grant) |
2024-01-31 |
JOOSS KARIN |
Officer |
648.85K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Point72 Asset Management, L.P. |
7.57M |
14.77M |
8.14% |
2023-06-29 |
Redmile Group, LLC |
6.86M |
13.38M |
7.37% |
2023-06-29 |
Blackrock Inc. |
6.21M |
12.12M |
6.68% |
2023-06-29 |
Vanguard Group Inc |
4.05M |
7.90M |
4.35% |
2023-06-29 |
Versant Venture Management, LLC |
3.56M |
6.94M |
3.83% |
2023-06-29 |
Avidity Partners Management, LP |
2.77M |
5.39M |
2.97% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
2.49M |
4.85M |
2.67% |
2023-08-30 |
iShares Russell 2000 ETF |
1.96M |
3.56M |
2.10% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.06M |
2.06M |
1.13% |
2023-08-30 |
iShares Russell 2000 Value ETF |
806.72K |
1.47M |
0.87% |
2023-07-30 |
Fidelity Small Cap Index Fund |
769.87K |
1.52M |
0.83% |
2023-08-30 |
Fidelity Select Portfolios - Biotechnology |
669.79K |
1.22M |
0.72% |